After years of treatment intensification, a new focus in metastatic hormone-sensitive prostate cancer is de-escalation. Trials like ADREAM are evaluating planned treatment interruptions for patients with excellent responses, aiming to provide 'treatment-free intervals' that improve quality of life without sacrificing efficacy.

A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.

For patients with biochemically recurrent prostate cancer, the decision to treat hinges on PSA doubling time. A doubling time of over two years carries a low risk of metastasis, often warranting observation. Conversely, a doubling time under three months indicates a high risk of metastasis within three years, necessitating intervention.

After years of successfully intensifying hormonal therapy, the focus in prostate cancer is shifting toward de-intensification. Researchers are exploring intermittent therapy for top responders and developing non-hormonal approaches like radioligands to spare patients the chronic, life-altering side effects of permanent castration.

When PSA levels rise after initial treatments, patients face the difficult realization that their cancer is likely a chronic condition to be managed, not a disease to be cured. This existential moment requires a fundamental shift in their approach and expectations for the rest of their lives.

The EMBARK study demonstrates that an intermittent approach to androgen deprivation therapy (ADT), especially with combination ADT and enzalutamide, can provide patients with low-volume metastatic disease a median of 1.5 years off therapy, improving quality of life without compromising outcomes.

The oral GnRH antagonist Relagolix allows for much quicker testosterone recovery (1-2 months vs. 3-6 for leuprolide). While beneficial in curative-intent settings, this rapid recovery is a double-edged sword that could shorten the "off-therapy" period during intermittent treatment for metastatic disease.

When using intermittent androgen deprivation, GnRH antagonists like relugolix are preferred over LHRH agonists like leuprolide. Antagonists allow for a much faster recovery of testosterone during off-treatment periods, which is a significant quality-of-life benefit for patients. With agonists, testosterone recovery can sometimes take years.

For biochemically recurrent (BCR) prostate cancer, which is often indolent, trials should not wait years to study treatment reduction. The NCI group universally agreed that de-escalation strategies—such as intermittent therapy—should be the default design from the outset, prioritizing quality of life and avoiding overtreatment.